Patents by Inventor Christopher Marohnic

Christopher Marohnic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DETECTION OF ANALYTES BY PROTEIN SWITCHES
    Publication number: 20220372542
    Abstract: Compositions of matter, methods, devices, systems and apparatus for detecting analytes are disclosed including, for example, protein switches and their use in an in vivo sensor. The protein switch can be used to determine a level of an analyte that is diagnostic for health and/or well-being of a subject.
    Type: Application
    Filed: October 1, 2020
    Publication date: November 24, 2022
    Inventors: Anthony Muerhoff, Thomas Leary, Christopher Marohnic, Barry Kreutz, Josie Corby, Benjamin Feldman, Tianmei Ouyang, Ahmed Wali, Oscar Alvizo
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 11428694
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: August 30, 2022
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20210231665
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200141937
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: May 24, 2019
    Publication date: May 7, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200033344
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10444242
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 15, 2019
    Assignees: ABBOTT LABORATORIES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10345311
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 10197573
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 5, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV NS3 RECOMBINANT ANTIGENS AND MUTANTS THEREOF FOR IMPROVED ANTIBODY DETECTION
    Publication number: 20170327803
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, M. Felicia Bogdan, Robin Gutierrez
  • HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
    Patent number: 9790478
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 17, 2017
    Assignee: Abbott Laboratories
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, M. Felisha Bogdan, Robin Gutierrez
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052183
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052184
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS, ANDREA BRANCH, FRANCIS ENG
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20160291020
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: March 23, 2016
    Publication date: October 6, 2016
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 9371374
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 21, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20140272931
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV NS3 RECOMBINANT ANTIGENS AND MUTANTS THEREOF FOR IMPROVED ANTIBODY DETECTION
    Publication number: 20140272932
    Abstract: The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: A. Scott Muerhoff, Christopher Marohnic, Larry Birkenmeyer, John Prostko, Felisha Bogdan, Robin Gutierrez